Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Cash & Equivalents (2016 - 2026)

Intellia Therapeutics has reported Cash & Equivalents over the past 12 years, most recently at $134.7 million for Q1 2026.

  • Quarterly Cash & Equivalents rose 6.16% to $134.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $134.7 million through Mar 2026, up 6.16% year-over-year, with the annual reading at $155.5 million for FY2025, 17.82% down from the prior year.
  • Cash & Equivalents was $134.7 million for Q1 2026 at Intellia Therapeutics, down from $155.5 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $523.5 million in Q4 2022 and troughed at $120.5 million in Q3 2024.
  • The 5-year median for Cash & Equivalents is $156.2 million (2025), against an average of $187.4 million.
  • The largest YoY upside for Cash & Equivalents was 317.18% in 2022 against a maximum downside of 57.82% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $523.5 million in 2022, then crashed by 56.69% to $226.7 million in 2023, then decreased by 16.57% to $189.2 million in 2024, then decreased by 17.82% to $155.5 million in 2025, then dropped by 13.36% to $134.7 million in 2026.
  • Per Business Quant, the three most recent readings for NTLA's Cash & Equivalents are $134.7 million (Q1 2026), $155.5 million (Q4 2025), and $193.4 million (Q3 2025).